Molecular structure of Cyclophosphamide Monohydrate, CAS Number: 6055-19-2
Cyclophosphamide Monohydrate (CAS 6055-19-2)
See product citations (3)
Alternate Names:
Bis(2-chloroethyl)phosphoramide cyclic propanolamide ester monohydrate
Application:
Cyclophosphamide Monohydrate is an immunosuppressive, cytotoxic apoptosis inducer
CAS Number:
6055-19-2
Purity:
≥97%
Molecular Weight:
279.10
Molecular Formula:
C7H15Cl2N2O2P•H2O
Supplemental Information:
This is classified as a Dangerous Good for transport and may be subject to additional shipping charges.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Product Citations
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
Cyclophosphamide monohydrate is an alkylating, cytotoxic agent experimentally shown to crosslink DNA, causing strand breakage and inducing mutations. It is also believed to possess immunosuppressive properties. Cyclophosphamide Monohydrate inhibits ALDH1 (aldehyde dehydrogenase 1) through its degradation product acrolein, as well as induces apoptosis in the rat thymus via the Fas/Fas ligand pathway.
Cyclophosphamide Monohydrate (CAS 6055-19-2) References
- Relatively low-dose cyclophosphamide is likely to induce apoptotic cell death in rat thymus through Fas/Fas ligand pathway. | Wang, GJ. and Cai, L. 1999. Mutat Res. 427: 125-33. PMID: 10393266
- Cyclophosphamide cardiotoxicity. | Kumar, S., et al. 1992. Natl Med J India. 5: 17-9. PMID: 1304238
- Cyclophosphamide and cancer: golden anniversary. | Emadi, A., et al. 2009. Nat Rev Clin Oncol. 6: 638-47. PMID: 19786984
- Cyclophosphamide in dermatology. | Kim, J. and Chan, JJ. 2017. Australas J Dermatol. 58: 5-17. PMID: 26806212
- The effect of cyclophosphamide on the immune system: implications for clinical cancer therapy. | Ahlmann, M. and Hempel, G. 2016. Cancer Chemother Pharmacol. 78: 661-71. PMID: 27646791
- Cyclophosphamide teratogenesis: a review. | Mirkes, PE. 1985. Teratog Carcinog Mutagen. 5: 75-88. PMID: 2859667
- Crystallization of Cyclophosphamide Monohydrate During Lyophilization. | Munjal, B., et al. 2019. J Pharm Sci. 108: 1195-1202. PMID: 30352215
- The Influence of Wuzhi Capsule on the Pharmacokinetics of Cyclophosphamide. | Chen, L., et al. 2022. Recent Pat Anticancer Drug Discov. 17: 195-203. PMID: 34758719
- The immunopharmacology of cyclophosphamide. | Shand, FL. 1979. Int J Immunopharmacol. 1: 165-71. PMID: 399479
- Cyclophosphamide cardiotoxicity. | von Bernuth, G., et al. 1980. Eur J Pediatr. 134: 87-90. PMID: 6997053
- Changes in solid-state structure of cyclophosphamide monohydrate induced by mechanical treatment and storage. | Ketolainen, J., et al. 1995. Pharm Res. 12: 299-304. PMID: 7784349
- Complications of cyclophosphamide therapy. | Langford, CA. 1997. Eur Arch Otorhinolaryngol. 254: 65-72. PMID: 9065658
- The effect of cyclophosphamide on Fas-mediated apoptosis. | Lee, JH., et al. 1997. J Korean Med Sci. 12: 185-9. PMID: 9250912
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Cyclophosphamide Monohydrate, 1 g | sc-202117 | 1 g | $43.00 | |||
Cyclophosphamide Monohydrate, 5 g | sc-202117A | 5 g | $90.00 |